公开(公告)号：WO2010101903A3

公开(公告)日：2011-01-13

申请号：PCT/US2010025898

申请日：2010-03-02

Applicant: TALECRIS BIOTHERAPEUTICS INC ,  KOEPF EDWARD ,  LINDSAY MYLES ,  SILVERSTEIN REBECCA ,  HUNT JENNIFER A ,  REBBEOR JAMES ,  ZIMMERMAN THOMAS P ,  MILLER CHARLES ,  CARONNA ANTHONY ,  STOKES KENYA

Inventor： KOEPF EDWARD ,  LINDSAY MYLES ,  SILVERSTEIN REBECCA ,  HUNT JENNIFER A ,  REBBEOR JAMES ,  ZIMMERMAN THOMAS P ,  MILLER CHARLES ,  CARONNA ANTHONY ,  STOKES KENYA

IPC: C07K1/18 ,  C12N9/50 ,  C12N15/57

CPC classification number: C12N9/6435 ,  C12Y304/21007

Abstract: Compositions and methods for preparing plasminogen, in particular recombinant plasminogen, and compositions and methods of utilizing same for preparing plasmin are provided.

Abstract translation: 提供了制备纤溶酶原的组合物和方法，特别是重组纤溶酶原，以及其用于制备纤溶酶的组合物和方法。

公开(公告)号：WO2009149199A3

公开(公告)日：2009-12-10

申请号：PCT/US2009/046152

申请日：2009-06-03

Applicant: TALECRIS BIOTHERAPEUTICS, INC. ,  KOEPF, Edward ,  ZIMMERMAN, Thomas, P.

Inventor： KOEPF, Edward ,  ZIMMERMAN, Thomas, P.

IPC: C12N9/68 ,  C12P21/06

Abstract: A streptokinase immobilized on a surface, in particular an immobilized plasmin- resistant streptokinase, and compositions, methods and kits of utilizing same for preparing plasmin are provided.

公开(公告)号：WO2009059082A3

公开(公告)日：2009-06-18

申请号：PCT/US2008081911

申请日：2008-10-31

Applicant: TALECRIS BIOTHERAPEUTICS INC ,  ARORA VIKRAM ,  PAMARTHI MOHAN ,  SCUDERI PHILIP

Inventor： ARORA VIKRAM ,  PAMARTHI MOHAN ,  SCUDERI PHILIP

IPC: A61K38/57 ,  C07K1/16 ,  C07K14/81

CPC classification number: C07K14/8125 ,  A61K38/00 ,  A61K38/47 ,  C12Y302/01035 ,  A61K2300/00

Abstract: The present invention provides a method for providing alpha-1 antitrypsin (a1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with a1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective amount of a1-AT to the subject. Also provided is a composition and article of manufacture comprising a1-AT, in particular a formulation suitable for subcutaneous administration of a1-AT.

Abstract translation: 本发明提供了一种向受试者提供α-1抗胰蛋白酶（a1-AT）的方法，特别是用于治疗或预防与受试者中a1-AT缺陷相关的病症或疾病的方法，其中该方法包括皮下 ，对受试者的治疗或预防有效量的a1-AT。 还提供了包含a1-AT的组合物和制品，特别是适于皮下施用a1-AT的制剂。

公开(公告)号：WO2008030825A3

公开(公告)日：2008-03-13

申请号：PCT/US2007/077566

申请日：2007-09-05

Applicant: TALECRIS BIOTHERAPEUTICS, INC. ,  LAING, Robert, Paul ,  EDWARDS, David, Clark ,  LOY, Larry, Howard

Inventor： LAING, Robert, Paul ,  EDWARDS, David, Clark ,  LOY, Larry, Howard

IPC: B65G21/02

Abstract: An apparatus (10) and method for handling and opening frangable containers (70) containing substantially solid contents is described. The apparatus includes a cutter (80) configured to sever an upper portion of a container from a lower portion of the container. The apparatus further includes a holder (62) for holding the lower portion of the container, a gripping device (20) for gripping the upper portion of the container as the container is severed by the cutter. The gripping device lifts the upper portion from the lower portion of the botle such that any portion of the solid contents within the upper portion is discharged to the lower portion of the container. The appartaus also can have a positioner for presenting the bottle to the cutter for cutting.

公开(公告)号：WO2005105990A2

公开(公告)日：2005-11-10

申请号：PCT/US2005013562

申请日：2005-04-21

Applicant: TALECRIS BIOTHERAPEUTICS INC ,  HUNT JENNIFER AUDREY ,  NOVOKHATNY VALERY

Inventor： HUNT JENNIFER AUDREY ,  NOVOKHATNY VALERY

IPC: C12N9/68

CPC classification number: C12N9/6435 ,  C12Y304/21007

Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

Abstract translation: 提供了与重组修饰的纤溶酶（原）分子相关的多核苷酸和多肽。 纤溶酶原（Ogen）分子在天然人纤溶酶原分子中存在活化位点的N-末端单个三环结构域，并显示与天然酶相关的赖氨酸结合和显着的酶特征。

公开(公告)号：WO2011060242A3

公开(公告)日：2011-10-13

申请号：PCT/US2010056496

申请日：2010-11-12

Applicant: TALECRIS BIOTHERAPEUTICS INC ,  BARNETT THOMAS

Inventor： BARNETT THOMAS

IPC: C07K19/00 ,  A61K38/17 ,  A61P7/00 ,  C12N15/62 ,  C12N15/63

CPC classification number: C07K14/755

Abstract: The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same.

Abstract translation: 本发明涉及用于制备FVIII并使用其的方法，组合物和试剂盒。 还提供了vWF多肽和编码它们的核酸分子。

公开(公告)号：WO2010118099A2

公开(公告)日：2010-10-14

申请号：PCT/US2010030191

申请日：2010-04-07

Applicant: TALECRIS BIOTHERAPEUTICS INC ,  LOY LARRY H

Inventor： LOY LARRY H

IPC: A61M39/10 ,  A61M39/14 ,  A61M39/16 ,  A61M39/18 ,  F16L21/00 ,  F16L55/00 ,  F16L55/10

CPC classification number: F16K13/04 ,  A61M39/14 ,  A61M39/18 ,  F16L2201/44

Abstract: A device is provided for ensuring the sterile integrity of two separate fluid pathways during interconnection of the two pathways with a two-part connector assembly. The two-part connector assembly is of the type which comprises a male portion and a female portion, each portion initially having a port covered and protected by a peel-away strip. The device comprises a base assembly, a connector clamp assembly mounted to the base assembly and configured for securing the two-part connector assembly in position for interconnection of the male and female portions, and a strip withdrawal assembly mounted to the base assembly and configured for simultaneous withdrawal of the peel-away strips from the ports of the male and female portions.

Abstract translation: 提供了一种装置，用于确保两个分离的流体通道在两个连接器组件的两个通路互连期间的无菌完整性。 两部分连接器组件是包括阳部分和阴部分的类型，每个部分最初具有被剥离带覆盖和保护的端口。 该装置包括基座组件，连接器夹具组件，其安装到基座组件并且被构造用于将两部分连接器组件固定在适当位置以使阳部分和阴部分互连;以及安装到基部组件上的条带退出组件， 剥离皮带从阳和阴部分的端口同时抽出。

公开(公告)号：WO2009073471A1

公开(公告)日：2009-06-11

申请号：PCT/US2008/084645

申请日：2008-11-25

Applicant: TALECRIS BIOTHERAPEUTICS, INC. ,  NOVOKHATNY, Valery

Inventor： NOVOKHATNY, Valery

IPC: C12N9/68 ,  C12N15/09

CPC classification number: C12N9/6435 ,  C07K2319/00 ,  C12N11/04 ,  C12Y304/21007

Abstract: Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that no foreign sequences are present, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

Abstract translation: 提供了与重组修饰的纤溶酶（原）分子相关的多核苷酸和多肽。 纤溶酶原（Ogen）分子具有与天然人纤溶酶原分子中存在的活化位点N末端的单个三环结构域，其组合使得不存在外来序列，并显示与天然酶相关的赖氨酸结合和显着的酶特征。

公开(公告)号：WO2007106617A2

公开(公告)日：2007-09-20

申请号：PCT/US2007/061269

申请日：2007-01-30

Applicant: TALECRIS BIOTHERAPEUTICS, INC. ,  SCUDERI, JR., Philip ,  SAFAVI, Afshin ,  LANGEVIN, Matthew, G.

Inventor： SCUDERI, JR., Philip ,  SAFAVI, Afshin ,  LANGEVIN, Matthew, G.

IPC: A61K39/00

CPC classification number: C07K16/065 ,  A01K2267/0312 ,  A61K39/39591 ,  A61K2039/505

Abstract: The invention relates to a method of treating or preventing disease associated with β- amyloid polypeptides comprising administration of an immunoglobulin preparation enriched in immunoglobulin M (IgM), and pharmaceutical compositions comprising such preparations.

Abstract translation: 本发明涉及治疗或预防与β淀粉样蛋白多肽相关的疾病的方法，包括施用富含免疫球蛋白M（IgM）的免疫球蛋白制剂，以及包含这种制剂的药物组合物。

公开(公告)号：WO2007047874A2

公开(公告)日：2007-04-26

申请号：PCT/US2006040940

申请日：2006-10-18

Applicant: TALECRIS BIOTHERAPEUTICS INC ,  SCUDERI JR PHILIP ,  ARORA VIKRAM ,  HUNT JENNIFER A ,  NOVOKHATNY VALERY ,  PETTEWAY JR STEPHEN R

Inventor： SCUDERI JR PHILIP ,  ARORA VIKRAM ,  HUNT JENNIFER A ,  NOVOKHATNY VALERY ,  PETTEWAY JR STEPHEN R

CPC classification number: C12Y304/21007 ,  A61K38/484 ,  C12N9/6435

Abstract: Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal tothe activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

Abstract translation: 提供了使用与重组修饰的纤溶酶（原）分子有关的多核苷酸和多肽的方法，包括涉及玻璃体切割术或玻璃体分解的方法。 纤溶酶（原）分子在天然人血纤维蛋白溶酶原分子的N端具有单个kringel结构域的活化位点，并显示与天然酶相关的赖氨酸结合和显着的酶特征。